Science ❯ Biotechnology ❯ Drug Development

Clinical Trials

GLP-1 Receptor Agonists VG-3927 Lung Cancer RSV and Cancer Vaccines BNT327 FDA Approvals Therapeutic Innovations Mast Cell Biology Phase I Trials Safety Regulations Antisense Oligonucleotide Conjugates Regulatory Approval Long-Acting Injectables Weight Loss Mechanisms Weight Loss Therapies Regulatory Approvals Animal Health Phase III Trials FGF21 Analog Liver Treatments Cancer Research Biosimilar Products Biosimilar Medicines Cancer Drugs Cell Therapy Anktiva

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

Analysts' targets signal sizable upside despite tighter cash and notable short interest.

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Weekly Parkinson’s Injection Secures Patent After Successful Lab Trials

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Sanofi to Acquire Vigil Neuroscience in $600M Deal to Advance Alzheimer’s Research